Prognostic value of serum soluble interleukin‐23 receptor and related T‐helper 17 cell cytokines in non‐small cell lung carcinoma
Open Access
- 5 February 2020
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 111 (4), 1093-1102
- https://doi.org/10.1111/cas.14343
Abstract
The signaling of interleukin (IL) 23 and its receptor (IL‐23R) play a crucial role in the development of cancers. However, the clinical significance of human serum soluble IL‐23R (sIL‐23R) and its relationship with IL‐23 are still not explored in non‐small cell lung cancer (NSCLC). In our study, sIL‐23R was firstly identified in the serum of NSCLC patients but not in healthy controls by proteomics. The IL‐23R mRNA and protein were upregulated in NSCLC cell lines and tissues tested by qPCR, Western blotting and IHC. The levels of sIL‐23R, IL‐23 and IL‐17 in 195 NSCLC patients’ serum were determined by ELISA, and high level of sIL‐23R was significantly associated with advanced N stage (P = 0.039), clinical stage (P = 0.007) and poor 5‐year survival rate. In vitro, sIL‐23R was shown binding to IL‐23 and the balance may affect patients N, T stage, overall survival (OS) and downstream cytokine IL‐17 in a potential antagonistic relationship. Although sIL‐23R, IL‐23 and IL‐17 were all associated with poor prognosis, only sIL‐23R/IL‐23 ratio [Hazard Ratio (HR): 1.945, 95% CI: 1.147‐3.299, P = 0.014] can be an independent factor for prognosis. Therefore, we identified fragments of soluble cytokine receptor of IL‐23R with affinity‐ability to its natural ligand IL‐23 in NSCLC patients’ serum. The balance between the two antagonists can work as a potential prognostic serum marker.Keywords
Funding Information
- National Natural Science Foundation of China-Yunnan Joint Fund (81271902)
This publication has 18 references indexed in Scilit:
- Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasisMolecular Cancer, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancerLung Cancer, 2013
- Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptorCarcinogenesis: Integrative Cancer Research, 2012
- A Naturally Occurring, Soluble Antagonist of Human IL-23 Inhibits the Development and In Vitro Function of Human Th17 CellsThe Journal of Immunology, 2010
- The Role of Inflammation in the Pathogenesis of Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Identification and characterization of multiple splice forms of the human interleukin-23 receptor α chain in mitogen-activated leukocytesGenes & Immunity, 2008
- Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosisNature, 2006
- Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cellsMolecular Cancer Therapeutics, 2005
- Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis VulgarisThe Journal of Experimental Medicine, 2004